Camp4 Therapeutics Corp cash flow statement
In fiscal 2025, Camp4 Therapeutics Corp's operations generated −$29.6m of cash; it spent $279,000 on capital projects, leaving free cash flow of −$29.8m.
Cash flow statement
| Fiscal year | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|
| Cash from operations | −44 | −46 | −30 | −29 |
| Depreciation and amortisation | 2 | 2 | 2 | 2 |
| Stock-based pay | 3 | 4 | 4 | 6 |
| Capital spending | 1 | 0 | 0 | 0 |
| Free cash flow | −45 | −46 | −30 | −29 |
| Free cash flow after stock pay | −48 | −50 | −34 | −34 |
| Shares issued | 0 | 76 | 58 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −10 | −11 | −14 | −10 | −11 | 6 | −11 | −13 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Stock-based pay | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −10 | −12 | −15 | −10 | −11 | 6 | −11 | −13 |
| Free cash flow after stock pay | −11 | −12 | −15 | −11 | −12 | 5 | −12 | −15 |
| Shares issued | 0 | 76 | 0 | 0 | — | — | — | — |
Compare with peers
- Curis Inc cash flow
- Ensysce Biosciences, Inc. cash flow
- Ocugen, Inc. cash flow
- DBV Technologies S.a. cash flow
- Dyadic International Inc cash flow
Head to head: CAMP vs CRISCAMP vs ENSCCAMP vs OCGNCAMP vs DBVT
More: Biotechnology stocks compared, Health Care sector, rankings of US companies